Prestige Consumer Healthcare Inc. (NYSE:PBH) Holdings Decreased by Leeward Investments LLC MA

Leeward Investments LLC MA cut its stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 4.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 359,898 shares of the company's stock after selling 16,782 shares during the quarter. Prestige Consumer Healthcare accounts for about 1.6% of Leeward Investments LLC MA's holdings, making the stock its 6th biggest holding. Leeward Investments LLC MA owned approximately 0.73% of Prestige Consumer Healthcare worth $30,940,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of PBH. CIBC Private Wealth Group LLC lifted its holdings in shares of Prestige Consumer Healthcare by 48.9% in the 4th quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company's stock worth $34,000 after acquiring an additional 152 shares during the last quarter. Opal Wealth Advisors LLC bought a new stake in shares of Prestige Consumer Healthcare in the 1st quarter worth approximately $38,000. Headlands Technologies LLC bought a new stake in shares of Prestige Consumer Healthcare in the 4th quarter worth approximately $40,000. McIlrath & Eck LLC lifted its holdings in shares of Prestige Consumer Healthcare by 19.1% in the 4th quarter. McIlrath & Eck LLC now owns 959 shares of the company's stock worth $75,000 after acquiring an additional 154 shares during the last quarter. Finally, Johnson Financial Group Inc. bought a new stake in shares of Prestige Consumer Healthcare in the 4th quarter worth approximately $93,000. 99.95% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

PBH has been the subject of a number of recent analyst reports. Royal Bank Of Canada upgraded shares of Prestige Consumer Healthcare to a "hold" rating in a report on Thursday, May 8th. Wall Street Zen upgraded shares of Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a report on Saturday. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $93.33.

Prestige Consumer Healthcare Trading Down 1.3%

Prestige Consumer Healthcare stock traded down $1.05 during mid-day trading on Monday, reaching $78.93. 359,188 shares of the company traded hands, compared to its average volume of 306,647. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.20 and a quick ratio of 2.82. The firm's 50 day moving average price is $84.17 and its 200 day moving average price is $82.43. The firm has a market capitalization of $3.90 billion, a price-to-earnings ratio of 18.40, a P/E/G ratio of 2.40 and a beta of 0.43. Prestige Consumer Healthcare Inc. has a 52-week low of $64.94 and a 52-week high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $1.32 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.30 by $0.02. The business had revenue of $296.52 million for the quarter, compared to the consensus estimate of $289.36 million. Prestige Consumer Healthcare had a net margin of 18.86% and a return on equity of 12.87%. The company's quarterly revenue was up 7.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.02 EPS. On average, analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.